Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe revision history now includes a new entry for v3.3.4 and removes v3.3.3 from the list, representing a minor update to the record's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedFooter changes include the addition of 'Revision: v3.3.3' and removal of the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' entry. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page header, indicating a minor site update.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check67 days agoChange DetectedRemoved the site-wide notice about government funding and NIH operating status. The banner previously informed users that data may be delayed and directed users to cc.nih.gov and opm.gov for updates.SummaryDifference0.4%

- Check81 days agoChange DetectedNew version entries appear in the Record History, reflecting ongoing updates to the study record (e.g., Study Status and Contacts/Locations), while the overall page structure remains the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.